Maze Therapeutics (MAZE) President & CMO Harold Bernstein Sells Shares

What Happened

• Harold Bernstein, President, R&D & Chief Medical Officer of Maze Therapeutics (MAZE), sold 9,705 shares in an open-market transaction on September 4, 2026. The weighted average sale price was $26.22 per share, resulting in proceeds of approximately $254,502. This was a sale (routine liquidity), not a purchase.

Key Details

• Transaction date: 2026-09-04 (filed on 2026-09-08; filing appears timely)
• Quantity and price: 9,705 shares sold; weighted average price $26.22; individual trades ranged $25.77–$26.42 per share
• Proceeds: ~$254,502
• Shares owned after transaction: Not specified in the provided filing
• Footnotes: Transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025. The reported price is a weighted average; the filer will provide a breakdown of shares sold at each separate price upon request.

Context

• The trade was done under a pre-established 10b5-1 plan, which generally means the sales were pre-arranged and may not reflect contemporaneous views on the company. Sales are common for insiders for liquidity/tax planning; purchases are typically viewed as a stronger signal of insider conviction.